1. Home
  2. BXP vs AXSM Comparison

BXP vs AXSM Comparison

Compare BXP & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Properties Inc.

BXP

Boston Properties Inc.

HOLD

Current Price

$51.96

Market Cap

10.3B

Sector

Real Estate

ML Signal

HOLD

Logo Axsome Therapeutics Inc.

AXSM

Axsome Therapeutics Inc.

HOLD

Current Price

$154.77

Market Cap

9.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXP
AXSM
Founded
1970
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.3B
9.0B
IPO Year
1998
2015

Fundamental Metrics

Financial Performance
Metric
BXP
AXSM
Price
$51.96
$154.77
Analyst Decision
Buy
Strong Buy
Analyst Count
19
17
Target Price
$73.58
$209.18
AVG Volume (30 Days)
2.6M
493.1K
Earning Date
04-29-2026
05-18-2026
Dividend Yield
5.31%
N/A
EPS Growth
1833.33
38.56
EPS
1.74
N/A
Revenue
$3,482,279,000.00
N/A
Revenue This Year
$10.94
$58.34
Revenue Next Year
$3.00
$54.30
P/E Ratio
$30.28
N/A
Revenue Growth
2.19
N/A
52 Week Low
$49.93
$86.99
52 Week High
$79.33
$191.50

Technical Indicators

Market Signals
Indicator
BXP
AXSM
Relative Strength Index (RSI) 30.22 31.90
Support Level N/A $148.14
Resistance Level $73.29 $191.13
Average True Range (ATR) 1.98 4.67
MACD -0.35 -1.37
Stochastic Oscillator 18.23 9.19

Price Performance

Historical Comparison
BXP
AXSM

About BXP Boston Properties Inc.

BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.

About AXSM Axsome Therapeutics Inc.

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Share on Social Networks: